ZURA · Zura Bio Ltd
$5.86
+0.11 (+1.83%)
At close · Aug 21
Market Cap
$551.02M
Shares
95.83M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.75
Open$5.81
Day$5.54–5.81
52W close$1.75–7.04
Avg vol 30d756K
Short int10.5M · 11.0% float · 19.6d
Short vol42%
DataMar 2023–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+12%
above
Price vs 50-day avg
+12%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
76%
mid-range
Momentum
relative strength
1-month return
+9%
trailing
6-month return
−13%
trailing
YTD return
+10%
this year
Relative strength
−24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.97% of float · ▲ +2.5% MoM · 19.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
96 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
EPS growth
−77%
Y/Y
Free cash flow
$-64.9M
Balance sheet
$109.4M
net cash
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+12%
Bullish
Price vs 50-day avg
+12%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
76%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.97% of float · ▲ +2.5% MoM · 19.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
96 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $6 · 76%
Range high $7
vs 200-day avg +12%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| TibuSHIELD participants randomized | 247 | Q2 2026 | — |
| TibuSURE participants randomized | 91 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZURA
this stock
Zura Bio Ltd
|
$551.02M | +9.7% | — | — | 11.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZURA | +2.1% | +8.7% | -13.1% | +5.9% | +9.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +4.1% | +5.4% | -24.3% | +3.8% | -2.1% |
Key facts
CIK
1855644
CUSIP
G9TY5A101
13F (30d)
96 filings
96 filers
Visit website
Investor relations